Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Ultragenyx makes and sells rare-disease medicines, mostly enzyme replacement therapies and gene therapies for a handful of serious genetic disorders.
Ultragenyx is a biotech company that hunts for treatments for diseases so rare that most doctors will never see a single case. It sells a small portfolio of medicines, mostly enzyme replacement therapies, which are drugs that replace a missing or broken protein in people born with a specific genetic defect. Its best-known products treat conditions like X-linked hypophosphatemia, a bone disease, and mucopolysaccharidosis, a group of inherited disorders that affect how the body breaks down certain sugars. The customers are tiny — sometimes just a few hundred or a few thousand patients worldwide — but the prices are very high, often hundreds of thousands of dollars per patient per year, and insurers and government health programs usually pay because there is no alternative.
The company is also betting heavily on gene therapy, which aims to fix the underlying genetic problem with a one-time treatment rather than a lifetime of infusions. That pipeline is expensive and risky: clinical trials can fail, regulators can demand more data, and manufacturing these therapies is genuinely hard. Recent years have brought both progress and setbacks — approvals and launches for some products, but also trial disappointments and delays that have weighed on the stock. Revenue has been growing as newer medicines ramp up, but the company still spends more than it earns, so it is not yet consistently profitable. It funds itself through cash on hand, product sales, and occasional borrowing or share sales, rather than dividends or buybacks.
Think of it as a boutique pharmacy for the unluckiest lottery winners — a business that serves a tiny number of people with enormous unmet need, charges a fortune, and pours most of that money back into finding the next cure. The central question for investors is whether its gene therapy bets pay off before its cash runs thin, and whether enough patients can be found and treated to make each new product worthwhile.
Saved answer · last researched 11 Oct 2026